7. apr. 2022 ... Sotrovimab (XEVUDY) is a monoclonal antibody treatment. Monoclonal antibodies are laboratory-made proteins that mimic our body's immune system ...

25. mar. 2022 ... The monoclonal antibody sotrovimab is no longer authorized by the FDA to treat COVID-19 in certain U.S. regions with high frequency of the ...

Sales of sotrovimab came in at 958 million pounds sterling ($1.26 billion) last year, with 89% of the figure coming in the fourth quarter.

10. feb. 2022 ... (Nasdaq: VIR) today announced that preclinical data suggest that sotrovimab, an investigational monoclonal antibody authorized for emergency use ...

11. apr. 2022 ... Sotrovimab monoclonal antibody has been demonstrated to reduce disease progression in high-risk patients with mild-to-moderate COVID-19 before ...

Sotrovimab Xevudy (VIR-7831, GSK4182136, S309) is a pan-sarbecovirus anti-SARS-CoV-2 monoclonal antibody treatment.

25. mar. 2022 ... Sotrovimab is an investigational SARS-CoV-2 neutralizing monoclonal antibody. The antibody binds to an epitope on SARS-CoV-2 shared with SARS- ...

23. mai 2022 ... Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe COVID-19 outcomes in non-hospitalised patients: an ...

16. feb. 2022 ... Sotrovimab mAb Limits Progression to Severe COVID Regardless of Serostatus. 2022 CROI, February 12-16 and 22-24, 2022. Mark Mascolini

Sotrovimab written consent form – Version 1.2 (8 Oct 2021) [Download PDF] Also available in ... Sotrovimab – Drug guideline – latest version available here ...